

SCIENTIFIC PROGRAM

SESSION LECTURE

No.38

A Step Toward the Next Generation of Cancer
Immunotherapy
Room: Phoenix Room 4

Cochair:
Bo Huang



Yonghong Wan



Day 3 October 21st (Monday) 09:00 – 12:30

Time	Speaker	Title
09:00-09:30	Bo Huang Chinese Academy of Medical Sciences & Peking Union Medical College, China	Manufacturing stem cell-like CAR T cells for treatment of solid tumors
09:30-10:00	Yonghong Wan McMaster University, Canada	Hidden hurdles in the development of cancer vaccines
10:00-10:30	Dongming Kuang Sun Yat-sen University, China	Pathogenic effects of cytotoxic T cells in tumors: regulation and functions
10:30-11:00	Tea Break	
11:00-11:30	Jun Wang New York University, USA	Probing Key Immune Feedback Modulators for Immunotherapy of Cancer and Beyond
11:30-12:00	Di Wang Zhejiang University, China	New insights into immunometabolism within tumor microenvironment
12:00-12:30	Guideng Li Institute of Systems Medicine/Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences, China	Cutting-Edge Innovations in TCR-T Cell Therapy



Bo Huang

tjhuangbo@hotmail.com

He is a professor and the deputy chairman of the Department of Immunology of the Chinese Academy of Medical Sciences & Peking Union Medical College. His research focuses on tumor immunology, immunotherapy, metabolism, mechanomedicine, and tumor cell microparticles. As a corresponding author, he published many high-profile research papers in *Science*, *Sci Immunol*, *Sci Transl Med*, *Cancer Cell*, *Mol Cell*, *Nat Mater*, *Nat Immunol*, *Nat Cell Biol*, *Nat Biomed Eng*, and so on. He developed drug-packaging tumor cell microparticles, which have been used to treat malignant pleural effusions and ascites in cancer patients with high efficacy and safety in the clinic.



Jun Wang

jwang133@gmail.com

Dr. Jun Wang is currently an Assistant Professor of Pathology at NYU Grossman School of Medicine. Dr. Wang possesses around two decades of expertise in immunotherapy, focusing on the discovery of novel immune receptor-ligand pathways and their utilization for treating cancer and other human diseases. In addition to his early experience with anti-4-1BB immunotherapy, he has characterized FGL1/LAG-3, Siglec-15, MHC-I membrane inhibitors, and SARS-CoV-2 myeloid receptors as potential mechanisms of immune evasion and targets for immunotherapy. He is the founder and scientific advisor for Remunix Inc., an advisor for BMS and Hanmi Pharmaceutical Ltd., an advisor and scientific co-founder for Rootpath Genomics, and a co-founder of BioSpark Group.



Yonghong Wan

wanyong@mcmaster.ca

Professor of Medicine at McMaster University where he leads a group of researchers working on the mechanisms by which the adaptive immune system recognizes and responds to tumors. His specific interests are the development of cancer vaccines using conventional and oncolytic viruses and their combination with other immunotherapies.



Di Wang

diwang@zju.edu.cn

Professor Di Wang (Qishi Distinguished Professor in Zhejiang University) is now the Executive Director of the Center for Infection and Immunity, Vice Dean of the School of Medicine. As a corresponding author, he has published many peer-reviewed papers in the high-impact scientific journals including *Nature*, *Cell*, *Immunity*, *Science Immunology*, *Cell Metabolism*, *Molecular Cell*, *Developmental Cell*, and *Nature Communications*. He has received many renowned prizes and supported by several highly competitive funds. He is currently a council member of the Chinese Society of Biochemistry and Molecular Biology, a member of the Molecular Immunology Division, a member of the Immunobiology Division of the Chinese Society of Cell Biology, a member of the Cell Metabolism Division, and a member of the Cell Death Research Division.



Dong-Ming Kuang

kdming@mail.sysu.edu.cn

School of Life Sciences, Sun Yat-sen University, China Professor Kuang's research focuses on the dynamic interactions between cancer cells and immune cells during the occurrence, development, and treatment of human hepatocellular carcinoma. They studied how human tumors dynamically educate infiltrating immune cells, with a focus on monocytes/macrophages, T cells, and B cells. These studies will provide important new insights into "immune editing" in human tumors, which will help in the rational design of effective immune based anti-cancer therapies.



Guideng Li

gd@ism.cams.cn

PhD, Principal Investigator at the Institute of Systems Medicine/Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences. Current research in the laboratory focuses on understanding the molecular mechanisms responsible for productive anti-tumor immune responses and developing new technologies and effective therapeutic strategies with potential clinical applications.